Patents Assigned to Institut National de la Sante et de la Recherche Medicale
  • Publication number: 20240132547
    Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.
    Type: Application
    Filed: April 2, 2023
    Publication date: April 25, 2024
    Applicants: Institut National De La Sante Et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Ecole Normale Superieure De Lyon, Universite Claude Bernard Lyon 1
    Inventors: Théophile OHLMANN, Philippe MANGEOT, Emiliano RICCI
  • Publication number: 20240130358
    Abstract: An organ perfusion and preservation system for use in preserving an organ from a donor, may include a fluid reservoir, a heat exchanger in fluid communication with the fluid reservoir and configured to selectively raise and lower a temperature of a perfusion fluid, an oxygenator configured to oxygenate the perfusion fluid, an inflow pump in fluid communication with the fluid reservoir and the oxygenator, a fluid inflow line configured to transport perfusion fluid from the oxygenator to the organ, a fluid outflow line configured to transport perfusion fluid away from the organ and back to the reservoir, an outflow pump in fluid communication with the fluid outflow line and the fluid reservoir, and a controller operatively connected to the inflow pump, the outflow pump, and the heat exchanger, wherein the controller is configured to select parameters to reversibly heat and reversibly cool the organ.
    Type: Application
    Filed: January 3, 2024
    Publication date: April 25, 2024
    Applicants: SORIN GROUP ITALIA S.R.L., SORBONNE UNIVERSITE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, ASSISTANCE PUBLIQUE- HOPITAUX DE PARIS
    Inventors: John F. Migliazza, Sandra Spiritelli, Olivier Scatton, Eric Savier, Claire Goumard
  • Publication number: 20240131138
    Abstract: Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors produced an antibody that is directed against a surface antigen (i.e., CD40) of an antigen presenting cell (i.e., dendritic cell) wherein the heavy chain and/or light chain is conjugated to the MOMP VS4 domain of Chlamydia trachomatis for its use as vaccine.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 25, 2024
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hopitaux de Paris (APHP), Baylor Research Institute, Universite Paris Est Creteil Val De Marne
    Inventors: Yves LEVY, Sylvain CARDINAUD, Mireille CENTLIVRE, Lydie DIEUDONNE, Sandra ZURAWSKI, Gérard ZURAWSKI
  • Publication number: 20240124532
    Abstract: Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors have set up candidate vaccines against Chlamydia trachomatis. In particular, the inventors have identified specific epitopes to be included in vaccine candidates thanks to in silico analysis of the amino-acid sequence of these proteins to map predicted MHC-I and -II epitopes by online software (NetMHC-4.0 and NetMHCII-2.3) and peptide binding prediction software. B cell epitopes were also mapped using online software (BepiPred-2.0 and Discotope). Finally, the inventors have generated some specific CD40 or Langerin antibodies comprising one or more identified epitope(s) of the present invention and that are suitable for vaccine purposes. Therefore, the present invention relates to Chlamydia trachomatis (Ct) antigenic polypeptides and uses thereof for vaccine purposes.
    Type: Application
    Filed: January 28, 2022
    Publication date: April 18, 2024
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hopitaux de Paris, Universite Paris Est Creteil Val De Marne, Baylor Research Institute
    Inventors: Yves LEVY, Sandra ZURAWSKI, Gérard ZURAWSKI, Mireille CENTLIVRE, Lydie DIEUDONNE, Sylvain CARDINAUD
  • Publication number: 20240116876
    Abstract: The present invention provides SOCE inhibitors that are useful as therapeutic agents in a variety of applications. The present invention also relates to pharmaceutical compositions, products and kits comprising such SOCE inhibitors, and methods of using the SOCE inhibitors in the treatment of a variety of diseases.
    Type: Application
    Filed: May 19, 2021
    Publication date: April 11, 2024
    Applicants: Institut National de la Santé et de la Recherche Médicale, Universite de Bretagne Occidentale, Ecole Nationale Superieure de Chimie de Rennes, Institut National des Sciences Appliquees de Rennes, Universite Nangui Abrogoua, Centre National de la Recherche Scientifique, Universite de Rennes 1
    Inventors: Jean Pierre Bazureau, Déliko Camille Dago, Lou Anna Voli, Olivier Mignen, Christophe Brigaudeau, Yves-Alain Berko
  • Patent number: 11951090
    Abstract: FGFR3-related chondrodysplasias represent a group of rare diseases. Among them, achondroplasia, a nonlethal form of chondrodysplasia, is the most common type of dwarfism. The mutation, which produce an increase of FGFR3 function, affects many tissues, most strikingly the cartilaginous growth plate and bone in the growing skeleton, leading to a variety of manifestations and complications. In attempt to find a new therapeutic approach for FGFR3-related chondrodysplasia, the inventors purified (?)-epicatechin from T. cacao and showed that (?)-epicatechin treatment significantly increases the length of the Fgfr3Y367C/+ femurs comparing to Fgfr3+/+ femurs and improves the whole growth plate cartilage. The present invention thus relates to the use of (?)-epicatechin for the treatment of FGFR3-related chondrodysplasias.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: April 9, 2024
    Assignees: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITÉ DE PARIS, FONDATION IMAGINE, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS, UNIVERSIDAD DE GRANADA
    Inventors: Laurence Legeai-Mallet, Antonio Segura Carretero, Maria De La Luz Cadiz Gurrea
  • Publication number: 20240109940
    Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.
    Type: Application
    Filed: November 22, 2023
    Publication date: April 4, 2024
    Applicants: Institut National De La Sante Et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Ecole Normale Superieure De Lyon, Universite Claude Bernard Lyon 1
    Inventors: Théophile OHLMANN, Philippe MANGEOT, Emiliano RICCI
  • Patent number: 11944445
    Abstract: A method for automatically detecting elements of interest in electrophysiological signals includes: delivering electrophysiological signals; producing a whitened time-frequency representation of the electrophysiological signals; setting a threshold; applying this threshold to the whitened time-frequency representation; and, in the whitened time-frequency representation, detecting local maxima that are higher than or equal to the applied threshold.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: April 2, 2024
    Assignees: UNIVERSITÉ D'AIX-MARSEILLE (AMU), INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, ASSISTANCE PUBLIQUE—HÔPITAUX DE MARSEILLE (AP-HM)
    Inventors: Nicolas Roehri, Christian George Benar, Fabrice Bartolomei
  • Patent number: 11945871
    Abstract: The present invention relates to humanized antibodies that specifically bind to human BTN3A and their use in treating cancer and infectious disorders.
    Type: Grant
    Filed: June 1, 2023
    Date of Patent: April 2, 2024
    Assignees: IMCHECK THERAPEUTICS SAS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE AIX MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS
    Inventors: Alemseged Truneh, Daniel Olive, Christine Pasero, Aude De Gassart
  • Patent number: 11944616
    Abstract: The present invention relates to compounds of formula (I): for use as peripheral NMDA receptor antagonists.
    Type: Grant
    Filed: May 26, 2022
    Date of Patent: April 2, 2024
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ PARIS-SACLAY, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), HOPITAL MARIE LANNELONGUE
    Inventors: Sylvia Cohen-Kaminsky, Marc Humbert, Sebastien Dumas, Gilles Bru-Mercier, Samir Messaoudi, Jean-Daniel Brion, Mouad Alami, Gilles Galvani
  • Publication number: 20240101618
    Abstract: The present invention relates to an isolated peptide consisting of a sequence of 3 to 39 amino acids derived from the amino acid sequence SEQ ID NO: 1, said peptide having a sequence of amino acids selected from the group consisting of: a) sequences of 3 to 39 amino acids comprising at least the residues 6 to 8 of SEQ ID NO: 1, and b) sequences of 3 to 39 amino acids having at least 70% identity with said sequence in a).
    Type: Application
    Filed: August 3, 2023
    Publication date: March 28, 2024
    Applicants: INSTITUT NATIONAL UNIVERSITAIRE JEAN-FRANCOIS CHAMPOLLION, UNIVERSITE TOULOUSE III - PAUL SABATIER, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE DE ROUEN-NORMANDIE
    Inventors: Khaddouj Benmoussa, Elsa Bonnafe, Agnès Coste, Jérôme Leprince, Bernard Pipy, Michel Treilhou
  • Publication number: 20240100048
    Abstract: The success of anti-tumor immune responses requires effector T cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10, and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing the biologically active form of chemokines as a strategy to enhance tumor immunotherapy.
    Type: Application
    Filed: December 7, 2023
    Publication date: March 28, 2024
    Applicants: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Rosa BARREIRA DA SILVA, Matthew ALBERT
  • Patent number: 11940578
    Abstract: An imaging method including: a) acquiring N successive positron emission tomography (PET) low resolution images ?i and simultaneously, N successive Ultrafast Ultrasound Imaging (UUI) images Ui of a moving object; b) determining from each UUI image Ui, the motion vector fields Mi that corresponds to the spatio-temporal geometrical transformation of the motion of the object; c) obtaining a final estimated high resolution image H of the object by iterative determination of a high resolution image Hn+1 obtained by applying several correction iterations to a current estimated high resolution image Hn, n being the number of iterations, starting from an initial estimated high resolution image H1 of the object, each correction iteration including at least: i) warping the estimated high resolution image Hn using the motion vector fields Mi to determine a set of low resolution reference images Lni; ii) determining a differential image Di by difference between each PET image ?i and the corresponding low resolution re
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: March 26, 2024
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS
    Inventors: Bertrand Tavitian, Mickaël Tanter, Mailyn Perez-Liva, Joaquin Lopez Herraiz, Jean Provost
  • Publication number: 20240081729
    Abstract: A sleep analyzer, method and system with reduced invasiveness and limited human intervention to monitor sleep in an intensive healthcare unit.
    Type: Application
    Filed: January 19, 2023
    Publication date: March 14, 2024
    Applicants: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), CENTRE HOSPITALIER UNIVERSITAIRE DE POITIERS, UNIVERSITE DE POITIERS, SOMNO ENGINEERING SAS
    Inventors: Xavier DROUOT, Maud Nicol DE LA BELLEISSUE
  • Patent number: 11926664
    Abstract: Monocytopoiesis is a hematological process that supplies the periphery with monocytes and subsequently with macrophages and monocyte-derived dendritic cells. Typically, monocytes circulate in the bloodstream for a very short time before undergoing apoptosis, however, stimulatory signals can trigger monocyte survival by inhibiting the apoptotic pathway, and thus contribute to the maintenance of the inflammatory response. Accordingly, there is a need for methods and pharmaceutical compositions for modulating monocytopoiesis. Now, the inventors show that type I interferons signaling promote the differentiation of monocyte-derived phagocytes at the level of their progenitors. Importantly, IFN-alpha and -beta were found to efficiently generate the development of monocyte-derived antigen-presenting cells while having no impact on the precursor activity of conventional dendritic cells. Accordingly, modulators of type I interferon (e.g.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: March 12, 2024
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT PASTEUR DE LILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ DE LILLE
    Inventors: Lionel Poulin, Corentin Lasseaux, Mathias Chamaillard
  • Patent number: 11912645
    Abstract: The invention is based on the discovery of a new bacterial compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Studying the mechanisms implicated in analgesic properties of the probiotic Escherichia coli strain Nissle 1917 (EcN), inventors characterized, the amino fatty acids produced by EcN, which display the Ecn analgesic properties. One of these compounds inhibits the hypersensitivity to colorectal distension induced by capsaicin, which is a very powerful nociceptive compound and acts via the GABA B receptor. Furthermore, inventors demonstrate that this compound is able to cross the cellular epithelial barrier (such as the intestinal epithelium). Thus, the invention relates to a lipopetide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: February 27, 2024
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS—, ECOLE NATIONALE VETERINAIRE DE TOULOUSE, UNIVERSITE PAUL SABATIER TOULOUSE III, INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, UNIVERSITE DE MONTPELLIER, ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER
    Inventors: Nicolas Cenac, Justine Bertrand-Michel, Teresa Perez-Berezo, Thierry Durand, Jean-Marie Galano, Julien Pujo, Eric Oswald, Patricia Martin, Pauline Le Faouder, Alexandre Guy
  • Publication number: 20240057969
    Abstract: An ultrasound probe holding device configured to attach to the head of an infant for transfontanellar imaging is disclosed, including a head pad configured to be in contact with the head of the infant and including a central opening, wherein the head pad is configured to receive an ultrasound probe; a pad squeezer, including a central opening and configured to cooperate with the head pad to allow an axial guidance of the head pad along a guidance axis substantially perpendicular to a surface tangent to the head of the infant; a device holder configured to be attached to the head of the infant and exert a downward force on the pad squeezer, along said guidance axis; and a repellent configured to exert a repellent force between the pad squeezer and the head pad when the device holder exerts the downward force on the pad squeezer.
    Type: Application
    Filed: December 13, 2021
    Publication date: February 22, 2024
    Applicants: ICONEUS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Centre National de la Recherche Scientifique, ECOLE SUPÉRIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS
    Inventors: Charlie Demene, Bruno-Felix Osmanski, Mickael Tanter, Jérôme Baranger, Olivier Baud
  • Patent number: 11905330
    Abstract: Autophagy is typically activated by starvation, allowing cells and organisms to mobilize their energy reserves. It is known that pharmacological modulation of autophagy represents a therapeutic potential. Here the inventors report that a protein that is released from cells in an unconventional, autophagy-dependent manner, namely, diazepam binding inhibitor (DBI), regulates autophagy. In particular, the inventors demonstrate that DBI inhibits autophagy and that the supply of recombinant DBI to mice enhanced glycolysis, enhanced lipogenesis, and inhibited fatty acid oxidation. The inventors show that neutralisation of DBI by a monoclonal antibody and an active immunization by means of an immunogenic DBI derivative eliciting autoantibodies induce autophagy and lead to metabolic changes that increase starvation-induced weight loss, reduce food intake upon refeeding, and reduce weight gain in response to hypercaloric diets.
    Type: Grant
    Filed: September 26, 2022
    Date of Patent: February 20, 2024
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), UNIVERSITÉ PARIS CITÉ, SORBONNE UNIVERSITÉ
    Inventors: Guido Kroemer, José Manuel Bravo San Pedro
  • Patent number: 11903982
    Abstract: Pseudomonas aeruginosa (PA) leads to chronic respiratory infections especially in patients with cystic fibrosis patients and chronic obstructive pulmonary disease (COPD), characterized by a high morbidity. After screening Lactobacilli coming from CF expectorations, on their capacity to inhibit two Pseudomonas aeruginosa (PA) virulence factors (elastase, pyocyanin), the inventors evaluated the effect of intranasal administration of Lactobacilli on PA murine pneumonia. The primary outcome was the bacterial lung load 24 hours after PA induced pneumonia. To understand the role of Lactobacillus, the chemokines, the pro and anti-inflammatory BAL rates were also measured. The administration of Lactobacilli cocktail 18 h prior the PA lung infection decreases significantly the lung bacterial load at 24 h post-infection. Although the mechanisms need to be deeply explored, an immunomodulation effect may be involved, notably through the recruitment of neutrophils.
    Type: Grant
    Filed: May 10, 2022
    Date of Patent: February 20, 2024
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), ETABLISSEMENT FRANCAIS DU SANG (EFS), UNIVERSITE DE BRETAGNE OCCIDENTALE, CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE BREST
    Inventors: Rozenn Le Berre, Marie-Sarah Fangous, Gwenaelle Le Blay, Geneviève Hery-Arnaud, Rosyne Lagrafeuille
  • Patent number: 11903382
    Abstract: Disclosed is a device for the perfusion of an organ, including: a container of fluid, containing an organ bathed in the perfusion fluid; a first path including an inlet, an outlet and a pump; and a second path including an inlet, an outlet and a pump. The “arterial” outlet of the first path has a diameter smaller than a diameter of the “portal” outlet of the second path. The device additionally includes, between the pump and the outlet of the first path and/or between the pump and the outlet of the second path, an oxygenation unit arranged to oxygenate the fluid emerging from the “arterial” outlet of the first path more than the fluid emerging from the “portal” outlet of the second path. The device can include a communication path between the first path and the second path in order to oxygenate the second path. Use in liver transplantation.
    Type: Grant
    Filed: January 11, 2023
    Date of Patent: February 20, 2024
    Assignees: UNIVERSITE DE TECHNOLOGIE DE COMPIEGNE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, SORBONNE UNIVERSITE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
    Inventors: Cécile Legallais, Patrick Paullier, Olivier Scatton, Eric Savier